PT4249069T - Formulação aquosa compreendendo 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia - Google Patents

Formulação aquosa compreendendo 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia

Info

Publication number
PT4249069T
PT4249069T PT231769688T PT23176968T PT4249069T PT 4249069 T PT4249069 T PT 4249069T PT 231769688 T PT231769688 T PT 231769688T PT 23176968 T PT23176968 T PT 23176968T PT 4249069 T PT4249069 T PT 4249069T
Authority
PT
Portugal
Prior art keywords
phenyl
dimorpholin
triazin
piperidin
dimethylamino
Prior art date
Application number
PT231769688T
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT4249069T publication Critical patent/PT4249069T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT231769688T 2018-06-07 2019-06-04 Formulação aquosa compreendendo 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia PT4249069T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862681722P 2018-06-07 2018-06-07
US201862754651P 2018-11-02 2018-11-02
US201962796133P 2019-01-24 2019-01-24
US201962841882P 2019-05-02 2019-05-02

Publications (1)

Publication Number Publication Date
PT4249069T true PT4249069T (pt) 2025-12-04

Family

ID=67402968

Family Applications (2)

Application Number Title Priority Date Filing Date
PT231769688T PT4249069T (pt) 2018-06-07 2019-06-04 Formulação aquosa compreendendo 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia
PT197428980T PT3810089T (pt) 2018-06-07 2019-06-04 Formulação aquosa compreendendo 1-(4-{[4- (dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT197428980T PT3810089T (pt) 2018-06-07 2019-06-04 Formulação aquosa compreendendo 1-(4-{[4- (dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia

Country Status (25)

Country Link
US (2) US12109308B2 (pt)
EP (3) EP3810089B1 (pt)
JP (2) JP7423200B2 (pt)
KR (2) KR102583563B1 (pt)
CN (2) CN116270452A (pt)
AU (2) AU2019283550B2 (pt)
BR (1) BR112020023891A2 (pt)
CA (1) CA3102527A1 (pt)
DK (2) DK3810089T3 (pt)
ES (2) ES3057278T3 (pt)
FI (2) FI4249069T3 (pt)
HR (2) HRP20251602T1 (pt)
HU (1) HUE063493T2 (pt)
IL (1) IL279270A (pt)
LT (2) LT4249069T (pt)
MX (2) MX2020013238A (pt)
NZ (1) NZ805649A (pt)
PL (2) PL4249069T3 (pt)
PT (2) PT4249069T (pt)
RS (2) RS67535B1 (pt)
SG (1) SG11202011256RA (pt)
SI (2) SI3810089T1 (pt)
SM (2) SMT202500473T1 (pt)
TW (1) TWI696469B (pt)
WO (1) WO2019234632A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
CA2454913A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
WO2005089094A2 (en) * 2003-11-21 2005-09-29 The Board Of Regents Of The University And Community College System Of Nevada Materials and methods for the preparation of anisotropically-ordered solids
US20070111965A1 (en) * 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE055928T2 (hu) * 2014-12-17 2022-01-28 Pfizer PI3K/MTOR-inhibitorok készítményei intravénás adagolásra
KR101829705B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
LT3672571T (lt) * 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą

Also Published As

Publication number Publication date
LT3810089T (lt) 2023-11-10
PL3810089T3 (pl) 2024-04-08
JP7423200B2 (ja) 2024-01-29
RS67535B1 (sr) 2026-01-30
SG11202011256RA (en) 2020-12-30
IL279270A (en) 2021-01-31
AU2022211854B2 (en) 2024-01-04
EP4649940A2 (en) 2025-11-19
SI3810089T1 (sl) 2023-11-30
SMT202300307T1 (it) 2023-11-13
PT3810089T (pt) 2023-08-23
JP7559162B2 (ja) 2024-10-01
HRP20251602T1 (hr) 2026-01-30
ES2956225T3 (es) 2023-12-15
JP2019218338A (ja) 2019-12-26
EP3810089B1 (en) 2023-08-02
EP4249069A2 (en) 2023-09-27
SI4249069T1 (sl) 2026-01-30
EP4649940A3 (en) 2026-01-21
WO2019234632A1 (en) 2019-12-12
DK3810089T3 (en) 2023-09-25
CN112218618B (zh) 2025-04-04
CA3102527A1 (en) 2019-12-12
TWI696469B (zh) 2020-06-21
AU2019283550B2 (en) 2022-06-16
EP3810089A1 (en) 2021-04-28
EP4249069B1 (en) 2025-11-19
CN116270452A (zh) 2023-06-23
CN112218618A (zh) 2021-01-12
PL4249069T3 (pl) 2026-02-23
NZ805649A (en) 2024-11-29
EP4249069A3 (en) 2023-11-29
JP2023138872A (ja) 2023-10-02
FI3810089T3 (fi) 2023-09-22
KR20210018341A (ko) 2021-02-17
AU2019283550A1 (en) 2020-12-10
SMT202500473T1 (it) 2026-01-12
MX2020013238A (es) 2021-02-22
MX2023012527A (es) 2023-10-31
US20250064732A1 (en) 2025-02-27
KR20230142810A (ko) 2023-10-11
NZ770000A (en) 2024-08-30
TW202000234A (zh) 2020-01-01
LT4249069T (lt) 2026-01-12
AU2022211854A1 (en) 2022-08-25
KR102583563B1 (ko) 2023-10-05
US20210212944A1 (en) 2021-07-15
HUE063493T2 (hu) 2024-01-28
DK4249069T3 (da) 2025-12-22
RS64692B1 (sr) 2023-11-30
FI4249069T3 (fi) 2025-12-29
BR112020023891A2 (pt) 2021-02-09
ES3057278T3 (en) 2026-02-27
HRP20231337T1 (hr) 2024-02-16
US12109308B2 (en) 2024-10-08

Similar Documents

Publication Publication Date Title
IL279270A (en) Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
HUE056743T2 (hu) 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény
PH12016501794A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL279914A (en) High-affinity isoform-selective TGFBETA1 inhibitors and their use
IL248924B (en) 1-((r4,s3)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-yl)-3-(4-methyl-3-(2-methylpyrimidine-5-yl)- 1-phenyl-h1-pyrazol-5-yl)urea as a trka kinase inhibitor
LT3442980T (lt) Heterocikliniai junginiai, kaip ret kinazės inhibitoriai
IL252368B (en) 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it
NZ719975A (en) Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound
IL291738A (en) Production method for 1-(4-(4-(4,3-dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy-piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used for this
DK3402784T3 (da) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
ZA202004311B (en) Pyrazole amide compound and application thereof, and fungicide
IL243650A0 (en) History of 1-(piperazine-1-yl)-2-([4,2,1]triazol-1-yl)-ethanone
IL310243A (en) 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
HK40107025A (en) 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
UA37000S (uk) Диван кутовий «bruno»
TH1601002081A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต
HK1242181A1 (en) Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n’-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
UA33872S (uk) Кутовий диван «renata»
UA35220S (uk) Диван кутовий «gretta»
UA34547S (uk) Диван кутовий «rafaella»